In other studies we also found that similar expression rates and lower than physiological expression levels of the neuropathy-associated gene such as GJB1 (connexin 32) were still adequate to provide a significant therapeutic benefit in disease models, although not a complete rescue (Kagiava et al., 2016, 2018). This evidence concerns the gene GJB1 and neuropathy.